

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 913 476 A2**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

06.05.1999 Bulletin 1999/18

(51) Int. Cl.<sup>6</sup>: **C12N 15/54**, C12N 9/10,

C12N 5/10, C07K 16/40,

C12Q 1/68, A61K 48/00

(21) Application number: **98203571.9**

(22) Date of filing: **22.10.1998**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**

Designated Extension States:

**AL LT LV MK RO SI**

(72) Inventors:

- **Zalacain, Magdalena,**  
**SmithKline Beecham Pharm.**  
**Collegeville, PA 19426-0989 (US)**
- **Brown, James Raymond,**  
**SmithKline Beecham Pharm.**  
**Collegeville, PA 19426-0989 (US)**

(30) Priority: **30.10.1997 US 961536**

(71) Applicant:

**SMITHKLINE BEECHAM CORPORATION**  
**Philadelphia Pennsylvania 19103 (US)**

(74) Representative:

**Mallalieu, Catherine Louise et al**  
**D. Young & Co.,**  
**21 New Fetter Lane**  
**London EC4A 1DA (GB)**

**(54) Ornithine carbamoyl transferase sequence and uses thereof**

(57) The invention provides ornithine carbamoyl-transferase polypeptides and DNA (RNA) encoding ornithine carbamoyltransferase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ornithine carbamoyltransferase polypeptides to screen for antibacterial compounds.

**EP 0 913 476 A2**

## Description

## FIELD OF THE INVENTION

5 [0001] This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, in these and in other regards, the invention relates to novel polynucleotides and polypeptides of the argF/arcB (ornithine carbamoyltransferase) family, hereinafter referred to as "ornithine carbamoyltransferase".

## 10 BACKGROUND OF THE INVENTION

[0002] The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid. Since  
15 its isolation more than 100 years ago, *Streptococcus pneumoniae* has been one of the more intensively studied microbes. For example, much of our early understanding that DNA is, in fact, the genetic material was predicated on the work of Griffith and of Avery, Macleod and McCarty using this microbe. Despite the vast amount of research with *S. pneumoniae*, many questions concerning the virulence of this microbe remain. It is particularly preferred to employ Streptococcal genes and gene products as targets for the development of antibiotics.

20 [0003] The frequency of *Streptococcus pneumoniae* infections has risen dramatically in the past 20 years. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate *Streptococcus pneumoniae* strains which are resistant to some or all of the standard antibiotics. This has created a demand for both new anti-microbial agents and diagnostic tests for this organism.

25 [0004] While certain Streptococcal factors associated with pathogenicity have been identified, e.g., capsule polysaccharides, peptidoglycans, pneumolysins, PspA Complement factor H binding component, autolysin, neuraminidase, peptide permeases, hydrogen peroxide, IgA1 protease, the list is certainly not complete. Moreover, very little is known concerning the temporal expression of such genes during infection and disease progression in a mammalian host. Discovering the sets of genes the bacterium is likely to be expressing at the different stages of infection, particularly when  
30 an infection is established, provides critical information for the screening and characterization of novel antibacterials which can interrupt pathogenesis. In addition to providing a fuller understanding of known proteins, such an approach will identify previously unrecognized targets.

[0005] The reaction catalyzed by ornithine carbamoyltransferase can participate in either the anabolism or the catabolism of arginine. The carbamoylation of ornithine, yielding citrulline, is involved in the biosynthetic sequence; the  
35 reverse reaction, the phosphorolysis of citrulline, is the second step of the arginine deiminase pathway. A number of microorganisms which can fulfill both of these functions has been found to possess two distinct ornithine carbamoyltransferases. The kinetic properties of these various enzymes have been determined. All of them, regardless of the role they play in the cell, catalyze both the synthesis and breakdown of citrulline. Enzymes involved in biosynthesis or degradation of aminoacids play a key role in bacterial primary metabolism and therefore inhibitors of these proteins could  
40 interfere with the infection process and have utility as antibacterial agents.

[0006] Clearly, there is a need for factors, such as the novel compounds of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity. Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists which can play a role in preventing, ameliorating or correcting infections, dysfunc-  
45 tions or diseases.

[0007] The polypeptides of the invention have amino acid sequence homology to a known *Lactobacillus plantarum* argF protein.

## SUMMARY OF THE INVENTION

50 [0008] It is an object of the invention to provide polypeptides that have been identified as novel ornithine carbamoyltransferase polypeptides by homology between the amino acid sequence set out in Table 1 [SEQ ID NO: 2] and a known amino acid sequence or sequences of other proteins such as *Lactobacillus plantarum* argF protein.

[0009] It is a further object of the invention to provide polynucleotides that encode ornithine carbamoyltransferase polypeptides, particularly polynucleotides that encode the polypeptide herein designated ornithine carbamoyltransferase.  
55

[0010] In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding ornithine carbamoyltransferase polypeptides comprising the sequence set out in Table 1 [SEQ ID NO:1] which includes a

full length gene, or a variant thereof.

[0011] In another particularly preferred embodiment of the invention there is a novel ornithine carbamoyltransferase protein from *Streptococcus pneumoniae* comprising the amino acid sequence of Table 1 [SEQ ID NO:2], or a variant thereof.

[0012] In accordance with another aspect of the invention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the *Streptococcus pneumoniae* 0100993 strain contained in the deposited strain.

[0013] A further aspect of the invention there are provided isolated nucleic acid molecules encoding ornithine carbamoyltransferase, particularly *Streptococcus pneumoniae* ornithine carbamoyltransferase, including mRNAs, cDNAs genomic DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

[0014] In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization. Among the particularly preferred embodiments of the invention are naturally occurring allelic variants of ornithine carbamoyltransferase and polypeptides encoded thereby.

[0015] Another aspect of the invention there are provided novel polypeptides of *Streptococcus pneumoniae* referred to herein as ornithine carbamoyltransferase as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof and compositions comprising the same.

[0016] Among the particularly preferred embodiments of the invention are variants of ornithine carbamoyltransferase polypeptide encoded by naturally occurring alleles of the ornithine carbamoyltransferase gene.

[0017] In a preferred embodiment of the invention there are provided methods for producing the aforementioned ornithine carbamoyltransferase polypeptides.

[0018] In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibacterial agents, including, for example, antibodies.

[0019] In accordance with certain preferred embodiments of the invention, there are provided products, compositions and methods for assessing ornithine carbamoyltransferase expression, treating disease, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid, assaying genetic variation, and administering a ornithine carbamoyltransferase polypeptide or polynucleotide to an organism to raise an immunological response against a bacteria, especially a *Streptococcus pneumoniae* bacteria.

[0020] In accordance with certain preferred embodiments of this and other aspects of the invention there are provided polynucleotides that hybridize to ornithine carbamoyltransferase polynucleotide sequences, particularly under stringent conditions.

[0021] In certain preferred embodiments of the invention there are provided antibodies against ornithine carbamoyltransferase polypeptides.

[0022] In other embodiments of the invention there are provided methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the invention comprising: contacting a polypeptide or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the polypeptide or polynucleotide to assess the binding to or other interaction with the compound, such binding or interaction being associated with a second component capable of providing a detectable signal in response to the binding or interaction of the polypeptide or polynucleotide with the compound; and determining whether the compound binds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detecting the presence or absence of a signal generated from the binding or interaction of the compound with the polypeptide or polynucleotide.

[0023] In accordance with yet another aspect of the invention, there are provided ornithine carbamoyltransferase agonists and antagonists, preferably bacteriostatic or bacteriocidal agonists and antagonists.

[0024] In a further aspect of the invention there are provided compositions comprising a ornithine carbamoyltransferase polynucleotide or a ornithine carbamoyltransferase polypeptide for administration to a cell or to a multicellular organism.

[0025] Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.

## GLOSSARY

[0026] The following definitions are provided to facilitate understanding of certain terms used frequently herein.

[0027] "Host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.

[0028] "Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 (1990). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. Analogously, by a polypeptide having an amino acid sequence having at least, for example, 95% identity to a reference amino acid sequence of SEQ ID NO:2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

[0029] "Isolated" means altered "by the hand of man" from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

[0030] "Polynucleotide(s)" generally refers to any polyribonucleotide or polydeoxynucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotide(s)" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and triple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded regions, or a mixture of single- and double-stranded regions. In addition, "polynucleotide" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. As used herein, the term "polynucleotide(s)" also includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotide(s)" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term "polynucleotide(s)" as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including, for example, simple and complex cells. "Polynucleotide(s)" also embraces short polynucleotides often referred to as oligonucleotide(s).

[0031] "Polypeptide(s)" refers to any peptide or protein comprising two or more amino acids joined to each other by

peptide bonds or modified peptide bonds. "Polypeptide(s)" refers to both short chains, commonly referred to as peptides, oligopeptides and oligomers and to longer chains generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene encoded amino acids. "Polypeptide(s)" include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill in the art. It will be appreciated that the same type of modification may be present in the same or varying degree at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains, and the amino or carboxyl termini. Modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins, such as arginylation, and ubiquitination. See, for instance, *PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993) and Wold, F., *Posttranslational Protein Modifications: Perspectives and Prospects*, pgs. 1-12 in *POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS*, B. C. Johnson, Ed., Academic Press, New York (1983); Seifter et al., *Meth. Enzymol.* 182:626-646 (1990) and Rattan et al., *Protein Synthesis: Posttranslational Modifications and Aging*, Ann. N.Y. Acad. Sci. 663: 48-62 (1992). Polypeptides may be branched or cyclic, with or without branching. Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well.

[0032] "Variant(s)" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.

## DESCRIPTION OF THE INVENTION

[0033] The invention relates to novel ornithine carbamoyltransferase polypeptides and polynucleotides as described in greater detail below. In particular, the invention relates to polypeptides and polynucleotides of a novel ornithine carbamoyltransferase of *Streptococcus pneumoniae*, which is related by amino acid sequence homology to *Lactobacillus plantarum* argF polypeptide. The invention relates especially to ornithine carbamoyltransferase having the nucleotide and amino acid sequences set out in Table 1 [SEQ ID NO: 1] and Table 1 [SEQ ID NO: 2] respectively, and to the ornithine carbamoyltransferase nucleotide sequences of the DNA in the deposited strain and amino acid sequences encoded thereby.

TABLE 1

## Ornithine carbamoyltransferase Polynucleotide and Polypeptide Sequences

(A) Sequences from *Streptococcus pneumoniae* ornithine carbamoyltransferase polynucleotide sequence [SEQ ID NO:1].

5'-1 ATGACAAATT CAGTATTCCA AGGACGCAGC TTCTTAGCAG AAAAAGACTT

51 TACCCGTGCA GAGTTAGAAT ACCTTATTGG TCTTTCAGCT CACTTGAAAG

101 ATTTGAAAAA ACGCAATATT CAACACCACT ACCTTGCTGG CAAGAATATC

151 GCTCTCCTAT TTGAAAAAAC ATCTACTCGT ACTCGTGCAG CCTTTACAAC

201 TGCGGCTATC GACCTTGGTG CTCACCCAGA ATACCTCGGA GCAAATGATA

251 TTCAGTTGGG TAAAAAAGAA TCTACTGAAG ATACTGCTAA AGTATTGGGA

301 CGTATGTTTG ACGGGATTGA ATTCCGCGGA TTCAGCCAAC GTATGGTTGA

351 AGAATTGGCA GAATTCTCAG GCGTTCCAGT ATGGAACGGT CTAAGTACG

401 AATGGCACCC AACTCAAATG CTCGCTGACT ACTTGACTGT TCAAGAAAAC

451 TTCGGTCGCT TGGAAGGCTT GACATTGGTA TACTGTGGTG ATGGACGTAA

501 CAACGTTGCC AACAGCTTGC TCGTAACAGG TGCTATCCTT GGTGTCAATG

551 TTCACATCTT CTCACCAAAA GAACTCTTCC CAGAAAAAGA AATCGTTGAA

601 TTGGCAGAAG GATTTGCTAA AGAAAGTGGC GCACATGTTC TCATCACTGA

651 AGATGCTGAT GAAGCAGTTA AAGATGCAGA CGTTCTTTAC ACAGACGTTT

701 GGGTATCAAT GGGTGAAGAA GACAAATTCG CAGAACGTGT AGCTCTTCTT  
5  
751 AAACCTTACC AAGTCAATAT GGAAGTAGTT AAAAAAGCAG GCAATGAAAA  
801 CTTGATCTTC CTACACTGCT TGCCAGCATT CCACGATACT CACACTGTTT  
10  
851 ATGGTAAAGA CGTTGCTGAA AAATTGGTG TAGAAGAAAT GGAAGTAACA  
901 GACGAAGTCT TCCGCAGCAA GTACGCTCGC CACTTCGATC AAGCAGAAAA  
15  
951 CCGTATGCAC ACTATCAAAG CTGTTATGGC TGCTACACTT GGTAACCTTT  
1001 ATATTCCTAA AGTATAA  
20

-3'

(B) Ornithine carbamoyltransferase polypeptide sequence deduced from the polynucleotide sequence in this table [SEQ ID NO:2].

5 NH<sub>2</sub>-1 MTNSVFQGRS FLAEKDFTRA ELEYLIGLSA HLKDLKKRNI QHHYLAGKNI

51 ALLFEKTSTR TRAAFTTAI DLGAHPEYLG ANDIQLGKKE STEDTAKVLG

10 101 RMFDGIEFRG FSQRMVEELA EFSGVPVWNG LTDEWHPTQM LADYLTVQEN

151 FGRLEGLTLV YCGDGRNNVA NSLLVTGAIL GNVNHIFSPK ELFPEKEIVE

15 201 LAEGFAKESG AHVLITEDAD EAVKDADVLY TDVWVSMGEE DKFAERVALL

251 KPYQVNMDLV KKAGNENLIF LHCLPAFHDT HTVYGKDAE KFGVEEM EVT

20 301 DEVFRSKYAR HFDQAENRMH TIKAVMAATL GNLYIPKV -COOH

(C) Polynucleotide sequence embodiments [SEQ ID NO:1].

25 X-(R<sub>1</sub>)<sub>n</sub>-1 ATGACAAATT CAGTATTCCA AGGACGCAGC TTCTTAGCAG AAAAAGACTT

51 TACCCGTGCA GAGTTAGAAT ACCTTATTGG TCTTTCAGCT CACTTGAAAG

30 101 ATTTGAAAAA ACGCAATATT CAACACCACT ACCTTGCTGG CAAGAATATC

151 GCTCTCCTAT TTGAAAAAAC ATCTACTCGT ACTCGTGCAG CCTTTACAAC

35 201 TGCGGCTATC GACCTTGGTG CTCACCCAGA ATACCTCGGA GCAAATGATA

251 TTCAGTTGGG TAAAAAAGAA TCTACTGAAG ATACTGCTAA AGTATTGGGA

40 301 CGTATGTTTG ACGGGATTGA ATTCCGCGGA TTCAGCCAAC GTATGGTTGA

351 AGAATTGGCA GAATTCTCAG GCGTTCCAGT ATGGAACGGT CTAAGTACG

45 401 AATGGCACCC AACTCAAATG CTCGCTGACT ACTTGACTGT TCAAGAAAAC

451 TTCGGTCGCT TGGAAGGCTT GACATTGGTA TACTGTGGTG ATGGACGTAA

50 501 CAACGTTGCC AACAGCTTGC TCGTAACAGG TGCTATCCTT GGTGTCAATG

55



551 TTCACATCTT CTCACCAAAA GAACTCTTCC CAGAAAAAGA AATCGTTGAA  
5 601 TTGGCAGAAG GATTTGCTAA AGAAAGTGGC GCACATGTTC TCATCACTGA  
651 AGATGCTGAT GAAGCAGTTA AAGATGCAGA CGTTCTTTAC ACAGACGTTT  
10 701 GGGTATCAAT GGGTGAAGAA GACAAATTCG CAGAACGTGT AGCTCTTCTT  
751 AAACCTTACC AAGTCAATAT GGACTTAGTT AAAAAAGCAG GCAATGAAAA  
15 801 CTTGATCTTC CTACACTGCT TGCCAGCATT CCACGATACT CACACTGTTT  
851 ATGGTAAAGA CGTTGCTGAA AAATTTGGTG TAGAAGAAAT GGAAGTAACA  
20 901 GACGAAGTCT TCCGCAGCAA GTACGCTCGC CACTTCGATC AAGCAGAAAA  
951 CCGTATGCAC ACTATCAAAG CTGTTATGGC TGCTACACTT GGTAACCTTT  
25 1001 ATATTCCTAA AGTA - (R<sub>2</sub>)<sub>n</sub>-Y

## (D) Polypeptide sequence embodiments [SEQ ID NO:2].

X-(R<sub>1</sub>)<sub>n</sub>-1 MTNSVFQGRS FLAEKDFTRA ELEYLIGLSA HLKDLKKRNI QHHYLAGKNI

51 ALLFEKTSTR TRAAFTTAAI DLGAHPEYLG ANDIQLGKKE STEDTAKVLG

101 RMFDGIEFRG FSQRMVEELA EFSGVPVWNG LTDEWHPTQM LADYLTQVEN

151 FGRLEGLTLV YCGDGRNVA NSLLVTGAIL GNVVHIFSPK ELFPEKEIVE

201 LAEGFAKESG AHVLITEDAD EAVKDADVLY TDVWVSMGEE DKFAERVALL

251 KPYQVNMDLV KKAGNENLIF LHCLPAFHDT HTVYGKDAE KFGVEEMEV

301 DEVFRSKYAR HFDQAENRMH TIKAVMAATL GNLYIPKV -(R<sub>2</sub>)<sub>n</sub>-Y

(E) Sequences from *Streptococcus pneumoniae* ornithine carbamoyltransferase polynucleotide ORF sequence [SEQ ID NO:3].

5'-

ATGACAAATTCAGTATTCCAAGGACGCAGCTTCTTAGCAGAAAAAGACTTTACCCGTGCAGAGTTAGAATACC  
TTATTGG

TCTTTCAGCTCACTTGAAAGATTGAAAAACGCAATATTCAACACCACTACCTTGCTGGCAAGAATATCGCT  
CTCCTAT

TTGAAAAACATCTACTCGTACTCGTGCAGCCTTTACAACGCGCTATCGACCTTGGTGCTACCCAGAATA  
CCTCGGA

GCAATGATATTCAGTTGGGTAAAAAGAATCTACTGAAGATACTGCTAAAGTATTGGGACGTATGTTTGACG  
GGATTGA

ATTCGCGGATTCAGCCAACGTTATGGTTGA-3'

## (F) Ornithine carbamoyltransferase polypeptide sequence deduced from the polynucleotide ORF sequence in this table [SEQ ID NO:4].

NH<sub>2</sub>-MTNSVFQGRSFLAEKDFTRALEYLIGLSAHLKDLKKRNIQHHYLAGKNIALLEKTSTRTRAAFTTAA  
IDLGAHPEYLGANDIQLGKKESTEDTAKVLGRMFDGIEFRGFSQRYG -COOH

## Deposited materials

[0034] A deposit containing a *Streptococcus pneumoniae* 0100993 strain has been deposited with the National Collections of Industrial and Marine Bacteria Ltd. (herein "NCIMB"), 23 St. Machar Drive, Aberdeen AB2 1RY, Scotland on 11 April 1996 and assigned deposit number 40794. The deposit was described as *Streptococcus pneumoniae* 0100993 on deposit. On 17 April 1996 a *Streptococcus pneumoniae* 0100993 DNA library in *E. coli* was similarly deposited with the NCIMB and assigned deposit number 40800. The *Streptococcus pneumoniae* strain deposit is referred to herein as "the deposited strain" or as "the DNA of the deposited strain."

[0035] The deposited strain contains the full length ornithine carbamoyltransferase gene. The sequence of the polynucleotides contained in the deposited strain, as well as the amino acid sequence of the polypeptide encoded thereby,

are controlling in the event of any conflict with any description of sequences herein.

[0036] The deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. The deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. §112.

[0037] A license may be required to make, use or sell the deposited strain, and compounds derived therefrom, and no such license is hereby granted.

## Polypeptides

[0038] The polypeptides of the invention include the polypeptide of Table 1 [SEQ ID NO:2] (in particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of ornithine carbamoyltransferase, and also those which have at least 70% identity to a polypeptide of Table 1 [SEQ ID NOS:2 and 4] or the relevant portion, preferably at least 80% identity to a polypeptide of Table 1 [SEQ ID NOS:2 and 4], and more preferably at least 90% similarity (more preferably at least 90% identity) to a polypeptide of Table 1 [SEQ ID NOS:2 and 4] and still more preferably at least 95% similarity (still more preferably at least 95% identity) to a polypeptide of Table 1 [SEQ ID NOS:2 and 4] and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 30 amino acids and more preferably at least 50 amino acids.

[0039] The invention also includes polypeptides of the formula set forth in Table 1 (D) [SEQ ID NO:2] wherein, at the amino terminus, X is hydrogen, and at the carboxyl terminus, Y is hydrogen or a metal, R<sub>1</sub> and R<sub>2</sub> is any amino acid residue, and n is an integer between 1 and 1000. Any stretch of amino acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.

[0040] A fragment is a variant polypeptide having an amino acid sequence that entirely is the same as part but not all of the amino acid sequence of the aforementioned polypeptides. As with ornithine carbamoyltransferase polypeptides fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region, a single larger polypeptide.

[0041] Preferred fragments include, for example, truncation polypeptides having a portion of an amino acid sequence of Table 1 [SEQ ID NOS:2 and 4], or of variants thereof such as a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus. Degradation forms of the polypeptides of the invention in a host cell, particularly a *Streptococcus pneumoniae*, are also preferred. Further preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

[0042] Also preferred are biologically active fragments which are those fragments that mediate activities of ornithine carbamoyltransferase, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those fragments that are antigenic or immunogenic in an animal, especially in a human. Particularly preferred are fragments comprising receptors or domains of enzymes that confer a function essential for viability of *Streptococcus pneumoniae* or the ability to initiate, or maintain cause disease in an individual, particularly a human.

[0043] Variants that are fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention.

## Polynucleotides

[0044] Another aspect of the invention relates to isolated polynucleotides, including the full length gene, that encode the ornithine carbamoyltransferase polypeptide having a deduced amino acid sequence of Table 1 [SEQ ID NOS:2 and 4] and polynucleotides closely related thereto and variants thereof.

[0045] Using the information provided herein, such as a polynucleotide sequence set out in Table 1 [SEQ ID NOS: 1 and 3], a polynucleotide of the invention encoding ornithine carbamoyltransferase polypeptide may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using *Streptococcus pneumoniae* 0100993 cells as starting material, followed by obtaining a full length clone. For example, to obtain a polynucleotide sequence of the invention, such as a sequence given in Table 1 [SEQ ID NOS:1 and 3], typically a library of clones of chromosomal DNA of *Streptococcus pneumoniae* 0100993 in *E.coli* or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stringent conditions. By

sequencing the individual clones thus identified with sequencing primers designed from the original sequence it is then possible to extend the sequence in both directions to determine the full gene sequence. Conveniently, such sequencing is performed using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70). Illustrative of the invention, the polynucleotide set out in Table 1 [SEQ ID NO:1] was discovered in a DNA library derived from *Streptococcus pneumoniae* 0100993.

[0046] The DNA sequence set out in Table 1 [SEQ ID NOS:1] contains an open reading frame encoding a protein having about the number of amino acid residues set forth in Table 1 [SEQ ID NO:2] with a deduced molecular weight that can be calculated using amino acid residue molecular weight values well known in the art. The polynucleotide of SEQ ID NO: 1, between nucleotide number 1 through number 1014 encodes the polypeptide of SEQ ID NO:2. The stop codon begins at nucleotide number 1015 of SEQ ID NO:1.11014

[0047] Ornithine carbamoyltransferase of the invention is structurally related to other proteins of the argF/arcB (ornithine carbamoyltransferase) family, as shown by the results of sequencing the DNA encoding ornithine carbamoyltransferase of the deposited strain. The protein exhibits greatest homology to *Lactobacillus plantarum* argF protein (GenBank accession no. X99978) among known proteins. Ornithine carbamoyltransferase of Table 1 [SEQ ID NO:2] has about 61% identity over its entire length and about 76% similarity over its entire length with the amino acid sequence of *Lactobacillus plantarum* argF polypeptide.

[0048] The invention provides a polynucleotide sequence identical over its entire length to the coding sequence in Table 1 [SEQ ID NO:1]. Also provided by the invention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a fragment in reading frame with other coding sequence, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence. The polynucleotide may also contain non-coding sequences, including for example, but not limited to non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences, termination signals, ribosome binding sites, sequences that stabilize mRNA, introns, polyadenylation signals, and additional coding sequence which encode additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al., *Proc. Natl. Acad. Sci., USA* 86: 821-824 (1989), or an HA tag (Wilson et al., *Cell* 37: 767 (1984)). Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.

[0049] A preferred embodiment of the invention is a polynucleotide of comprising nucleotide 1 to 1014 or 1015 set forth in SEQ ID NO:1 of Table 1 which encode the ornithine carbamoyltransferase polypeptide.

[0050] The invention also includes polynucleotides of the formula set forth in Table 1 (C)[SEQ ID NO:1] wherein, at the 5' end of the molecule, X is hydrogen, and at the 3' end of the molecule, Y is hydrogen or a metal, R<sub>1</sub> and R<sub>2</sub> is any nucleic acid residue, and n is an integer between 1 and 1000. Any stretch of nucleic acid residues denoted by either R group, where n is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.

[0051] The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the *Streptococcus pneumoniae* ornithine carbamoyltransferase having the amino acid sequence set out in Table 1 [SEQ ID NO:2]. The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, interrupted by integrated phage or an insertion sequence or editing) together with additional regions, that also may contain coding and/or non-coding sequences.

[0052] The invention further relates to variants of the polynucleotides described herein that encode for variants of the polypeptide having the deduced amino acid sequence of Table 1 [SEQ ID NO:2]. Variants that are fragments of the polynucleotides of the invention may be used to synthesize full-length polynucleotides of the invention.

[0053] Further particularly preferred embodiments are polynucleotides encoding ornithine carbamoyltransferase variants, that have the amino acid sequence of ornithine carbamoyltransferase polypeptide of Table 1 [SEQ ID NO:2] in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, deleted or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of ornithine carbamoyltransferase.

[0054] Further preferred embodiments of the invention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encoding ornithine carbamoyltransferase polypeptide having an amino acid sequence set out in Table 1 [SEQ ID NOS:2 and 4], and polynucleotides that are complementary to such polynucleotides. Alternatively, most highly preferred are polynucleotides that comprise a region that is at least 80% identical over its entire length to a polynucleotide encoding ornithine carbamoyltransferase polypeptide of the deposited strain and polynucleotides complementary thereto. In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are espe-

cially preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

[0055] Preferred embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by the DNA of Table 1 [SEQ ID NO:1].

[0056] The invention further relates to polynucleotides that hybridize to the herein above-described sequences. In this regard, the invention especially relates to polynucleotides that hybridize under stringent conditions to the herein above-described polynucleotides. As herein used, the terms "stringent conditions" and "stringent hybridization conditions" mean hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences.

An example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1x SSC at about 65°C. Hybridization and wash conditions are well known and exemplified in Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein.

[0057] The invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:3 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:1 or a fragment thereof; and isolating said DNA sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and primers described elsewhere herein.

[0058] As discussed additionally herein regarding polynucleotide assays of the invention, for instance, polynucleotides of the invention as discussed above, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding ornithine carbamoyltransferase and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the ornithine carbamoyltransferase gene. Such probes generally will comprise at least 15 bases. Preferably, such probes will have at least 30 bases and may have at least 50 bases. Particularly preferred probes will have at least 30 bases and will have 50 bases or less.

[0059] For example, the coding region of the ornithine carbamoyltransferase gene may be isolated by screening using the DNA sequence provided in SEQ ID NO: 1 to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

[0060] The polynucleotides and polypeptides of the invention may be employed, for example, as research reagents and materials for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herein relating to polynucleotide assays.

[0061] Polynucleotides of the invention that are oligonucleotides derived from the sequences of SEQ ID NOS:1 and/or 2 may be used in the processes herein as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed in bacteria in infected tissue. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained.

[0062] The invention also provides polynucleotides that may encode a polypeptide that is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in vivo*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

[0063] A precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

[0064] In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

#### Vectors, host cells, expression

[0065] The invention also relates to vectors that comprise a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the invention.

[0066] For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis et al., *BASIC METHODS IN MOLECULAR BIOLOGY*, (1986) and Sambrook et al., *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection.

[0067] Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, enterococci *E. coli*, streptomyces and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.

[0068] A great variety of expression systems can be used to produce the polypeptides of the invention. Such vectors include, among others, chromosomal, episomal and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression system constructs may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard. The appropriate DNA sequence may be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL*, (*supra*).

[0069] For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.

[0070] Polypeptides of the invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding protein may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

#### Diagnostic Assays

[0071] This invention is also related to the use of the ornithine carbamoyltransferase polynucleotides of the invention for use as diagnostic reagents. Detection of ornithine carbamoyltransferase in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of a disease. Eukaryotes (herein also "individual(s)"), particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism comprising the ornithine carbamoyltransferase gene may be detected at the nucleic acid level by a variety of techniques.

[0072] Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification technique prior to analysis. RNA or cDNA may also be used in the same ways. Using amplification, characterization of the species and strain of prokaryote present in an individual, may be made by an analysis of the genotype of the prokaryote gene. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the genotype of a reference sequence. Point mutations can be identified by hybridizing amplified DNA to labeled ornithine carbamoyltransferase polynucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers et al., *Science*, 230: 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and S1 protection or a chemical cleavage method. See, e.g., Cotton et al., *Proc. Natl. Acad. Sci., USA*, 85: 4397-4401 (1985).

[0073] Cells carrying mutations or polymorphisms in the gene of the invention may also be detected at the DNA level by a variety of techniques, to allow for serotyping, for example. For example, RT-PCR can be used to detect mutations. It is particularly preferred to used RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan. RNA or cDNA may also be used for the same purpose, PCR or RT-PCR. As an example, PCR primers complementary to a nucleic acid encoding ornithine carbamoyltransferase can be used to identify and analyze mutations.

Examples of representative primers are shown below in Table 2.

Table 2

Primers for amplification of ornithine carbamoyltransferase polynucleotides	
SEQ ID NO	PRIMER SEQUENCE
5	5' AAAAACGCAATATTCAACACCACT -3'
6	5' TCCTTCTGCCAATTCAACGAT -3'

[0074] The invention further provides these primers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end. These primers may be used for, among other things, amplifying ornithine carbamoyltransferase DNA isolated from a sample derived from an individual. The primers may be used to amplify the gene isolated from an infected individual such that the gene may then be subject to various techniques for elucidation of the DNA sequence. In this way, mutations in the DNA sequence may be detected and used to diagnose infection and to serotype and/or classify the infectious agent.

[0075] The invention further provides a process for diagnosing, disease, preferably bacterial infections, more preferably infections by *Streptococcus pneumoniae*, and most preferably otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid, comprising determining from a sample derived from an individual a increased level of expression of polynucleotide having the sequence of Table 1 [SEQ ID NO: 1]. Increased or decreased expression of ornithine carbamoyltransferase polynucleotide can be measured using any one of the methods well known in the art for the quantitation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.

[0076] In addition, a diagnostic assay in accordance with the invention for detecting over-expression of ornithine carbamoyltransferase protein compared to normal control tissue samples may be used to detect the presence of an infection, for example. Assay techniques that can be used to determine levels of a ornithine carbamoyltransferase protein, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

#### Antibodies

[0077] The polypeptides of the invention or variants thereof, or cells expressing them can be used as an immunogen to produce antibodies immunospecific for such polypeptides. "Antibodies" as used herein includes monoclonal and polyclonal antibodies, chimeric, single chain, simianized antibodies and humanized antibodies, as well as Fab fragments, including the products of an Fab immunoglobulin expression library.

[0078] Antibodies generated against the polypeptides of the invention can be obtained by administering the polypeptides or epitope-bearing fragments, analogues or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique known in the art that provides antibodies produced by continuous cell line cultures can be used. Examples include various techniques, such as those in Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975); Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, pg. 77-96 in *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc. (1985).

[0079] Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies.

[0080] Alternatively phage display technology may be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-ornithine carbamoyltransferase or from naive libraries (McCafferty, J. *et al.*, (1990), *Nature* 348, 552-554; Marks, J. *et al.*, (1992) *Biotechnology* 10, 779-783). The affinity of these antibodies can also be improved by chain shuffling (Clackson, T. *et al.*, (1991) *Nature* 352, 624-628).

[0081] If two antigen binding domains are present each domain may be directed against a different epitope - termed 'bispecific' antibodies.

[0082] The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptides to purify the polypeptides by affinity chromatography.

[0083] Thus, among others, antibodies against ornithine carbamoyltransferase- polypeptide may be employed to treat infections, particularly bacterial infections and especially otitis media, conjunctivitis, pneumonia, bacteremia, meningi-

tis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid.

[0084] Polypeptide variants include antigenically, epitopically or immunologically equivalent variants that form a particular aspect of this invention. The term "antigenically equivalent derivative" as used herein encompasses a polypeptide or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protein or polypeptide according to the invention, interfere with the immediate physical interaction between pathogen and mammalian host. The term "immunologically equivalent derivative" as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical interaction between pathogen and mammalian host.

[0085] The polypeptide, such as an antigenically or immunologically equivalent derivative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken. The fusion protein may provide stability to the polypeptide. The antigen may be associated, for example by conjugation, with an immunogenic carrier protein for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH). Alternatively a multiple antigenic peptide comprising multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier.

[0086] Preferably, the antibody or variant thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized"; where the complementarity determining region(s) of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody, for example as described in Jones, P. et al. (1986), *Nature* 321, 522-525 or Tempest et al., (1991) *Biotechnology* 9, 266-273.

[0087] The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al., *Hum Mol Genet* 1992, 1:363, Manthorpe et al., *Hum. Gene Ther.* 1993:4, 419), delivery of DNA complexed with specific protein carriers (Wu et al., *J Biol Chem.* 1989: 264, 16985), coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef, *PNAS USA*, 1986:83,9551), encapsulation of DNA in various forms of liposomes (Kaneda et al., *Science* 1989:243,375), particle bombardment (Tang et al., *Nature* 1992, 356:152, Eisenbraun et al., *DNA Cell Biol* 1993, 12:791) and *in vivo* infection using cloned retroviral vectors (Seeger et al., *PNAS USA* 1984:81,5849).

#### Antagonists and agonists - assays and molecules

[0088] Polypeptides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, e.g., Coligan et al., *Current Protocols in Immunology* 1(2): Chapter 5 (1991).

[0089] The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of ornithine carbamoyltransferase polypeptides or polynucleotides, particularly those compounds that are bacteriostatic and/or bacteriocidal. The method of screening may involve high-throughput techniques. For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, comprising ornithine carbamoyltransferase polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that may be a ornithine carbamoyltransferase agonist or antagonist. The ability of the candidate molecule to agonize or antagonize the ornithine carbamoyltransferase polypeptide is reflected in decreased binding of the labeled ligand or decreased production of product from such substrate. Molecules that bind gratuitously, i.e., without inducing the effects of ornithine carbamoyltransferase polypeptide are most likely to be good antagonists. Molecules that bind well and increase the rate of product production from substrate are agonists. Detection of the rate or level of production of product from substrate may be enhanced by using a reporter system. Reporter systems that may be useful in this regard include but are not limited to colorimetric labeled substrate converted into product, a reporter gene that is responsive to changes in ornithine carbamoyltransferase polynucleotide or polypeptide activity, and binding assays known in the art.

[0090] Another example of an assay for ornithine carbamoyltransferase antagonists is a competitive assay that combines ornithine carbamoyltransferase and a potential antagonist with ornithine carbamoyltransferase-binding molecules, recombinant ornithine carbamoyltransferase binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. Ornithine carbamoyltransferase can be labeled, such as by radioactivity or a colorimetric compound, such that the number of ornithine carbamoyltransferase molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

[0091] Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide or polypeptide of the invention and thereby inhibit or extinguish its activity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same



sites on a binding molecule, such as a binding molecule, without inducing ornithine carbamoyltransferase-induced activities, thereby preventing the action of ornithine carbamoyltransferase by excluding ornithine carbamoyltransferase from binding.

[0092] Potential antagonists include a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules (see Okano, *J. Neurochem.* 56: 560 (1991); *OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION*, CRC Press, Boca Raton, FL (1988), for a description of these molecules). Preferred potential antagonists include compounds related to and variants of ornithine carbamoyltransferase.

[0093] Each of the DNA sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein, upon expression, can be used as a target for the screening of antibacterial drugs. Additionally, the DNA sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

[0094] The invention also provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection. In particular the molecules of the invention may be used in the prevention of adhesion of bacteria, in particular gram positive bacteria, to mammalian extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block ornithine carbamoyltransferase protein-mediated mammalian cell invasion by, for example, initiating phosphorylation of mammalian tyrosine kinases (Rosenshine *et al.*, *Infect. Immun.* 60:2211 (1992); to block bacterial adhesion between mammalian extracellular matrix proteins and bacterial ornithine carbamoyltransferase proteins that mediate tissue damage and; to block the normal progression of pathogenesis in infections initiated other than by the implantation of indwelling devices or by other surgical techniques.

[0095] The antagonists and agonists of the invention may be employed, for instance, to inhibit and treat otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid.

[0096] *Helicobacter pylori* (herein *H. pylori*) bacteria infect the stomachs of over one-third of the world's population causing stomach cancer, ulcers, and gastritis (International Agency for Research on Cancer (1994) Schistosomes, Liver Flukes and *Helicobacter Pylori* (International Agency for Research on Cancer, Lyon, France; <http://www.uicc.ch/ecp/ecp2904.htm>). Moreover, the international Agency for Research on Cancer recently recognized a cause-and-effect relationship between *H. pylori* and gastric adenocarcinoma, classifying the bacterium as a Group I (definite) carcinogen. Preferred antimicrobial compounds of the invention (agonists and antagonists of ornithine carbamoyltransferase) found using screens provided by the invention, particularly broad-spectrum antibiotics, should be useful in the treatment of *H. pylori* infection. Such treatment should decrease the advent of *H. pylori*-induced cancers, such as gastrointestinal carcinoma. Such treatment should also cure gastric ulcers and gastritis.

## Vaccines

[0097] Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal which comprises inoculating the individual with ornithine carbamoyltransferase, or a fragment or variant thereof, adequate to produce antibody and/or T cell immune response to protect said individual from infection, particularly bacterial infection and most particularly *Streptococcus pneumoniae* infection. Also provided are methods whereby such immunological response slows bacterial replication. Yet another aspect of the invention relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector to direct expression of ornithine carbamoyltransferase, or a fragment or a variant thereof, for expressing ornithine carbamoyltransferase, or a fragment or a variant thereof *in vivo* in order to induce an immunological response, such as, to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not. One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid.

[0098] A further aspect of the invention relates to an immunological composition which, when introduced into an individual capable or having induced within it an immunological response, induces an immunological response in such individual to a ornithine carbamoyltransferase or protein coded therefrom, wherein the composition comprises a recombinant ornithine carbamoyltransferase or protein coded therefrom comprising DNA which codes for and expresses an antigen of said ornithine carbamoyltransferase or protein coded therefrom. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells.

[0099] An ornithine carbamoyltransferase polypeptide or a fragment thereof may be fused with co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties. Thus fused recombinant protein, preferably further comprises an antigenic co-protein, such as lipoprotein D from *Hemophilus influenzae*, Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubilize the protein and facilitate production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system. The co-protein may be attached to either the amino or carboxy terminus of the first protein.

[0100] Provided by this invention are compositions, particularly vaccine compositions, and methods comprising the polypeptides or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y. *et al.* Science 273: 352 (1996).

[0101] Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof which have been shown to encode non-variable regions of bacterial cell surface proteins in DNA constructs used in such genetic immunization experiments in animal models of infection with *Streptococcus pneumoniae* will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly *Streptococcus pneumoniae* infection, in mammals, particularly humans.

[0102] The polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue. Examples of tissue damage include wounds in skin or connective tissue caused, e.g., by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagina.

[0103] The invention also includes a vaccine formulation which comprises an immunogenic recombinant protein of the invention together with a suitable carrier. Since the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

[0104] While the invention has been described with reference to certain ornithine carbamoyltransferase protein, it is to be understood that this covers fragments of the naturally-occurring protein and similar proteins with additions, deletions or substitutions which do not substantially affect the immunogenic properties of the recombinant protein.

#### Compositions, kits and administration

[0105] The invention also relates to compositions comprising the polynucleotide or the polypeptides discussed above or their agonists or antagonists. The polypeptides of the invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a polypeptide of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration. The invention further relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

[0106] Polypeptides and other compounds of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

[0107] The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.

[0108] In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

[0109] Alternatively the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols,

and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.

[0110] For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

[0111] In-dwelling devices include surgical implants, prosthetic devices and catheters, i.e., devices that are introduced to the body of an individual and remain in position for an extended time. Such devices include, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospinal fluid shunts, urinary catheters, continuous ambulatory peritoneal dialysis (CAPD) catheters.

[0112] The composition of the invention may be administered by injection to achieve a systemic effect against relevant bacteria shortly before insertion of an in-dwelling device. Treatment may be continued after surgery during the in-body time of the device. In addition, the composition could also be used to broaden perioperative cover for any surgical technique to prevent bacterial wound infections, especially *Streptococcus pneumoniae* wound infections.

[0113] Many orthopaedic surgeons consider that humans with prosthetic joints should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia. Late deep infection is a serious complication sometimes leading to loss of the prosthetic joint and is accompanied by significant morbidity and mortality. It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics in this situation.

[0114] In addition to the therapy described above, the compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis.

[0115] Alternatively, the composition of the invention may be used to bathe an indwelling device immediately before insertion. The active agent will preferably be present at a concentration of 1 µg/ml to 10mg/ml for bathing of wounds or indwelling devices.

[0116] A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.5-5 microgram/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals.

[0117] Each reference disclosed herein is incorporated by reference herein in its entirety. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety.

## EXAMPLES

[0118] The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples are illustrative, but do not limit the invention.

### Example 1 Strain selection, Library Production and Sequencing

[0119] The polynucleotide having the DNA sequence given in SEQ ID NO:1 was obtained from a library of clones of chromosomal DNA of *Streptococcus pneumoniae* in *E. coli*. The sequencing data from two or more clones containing overlapping *Streptococcus pneumoniae* DNAs was used to construct the contiguous DNA sequence in SEQ ID NO:1. Libraries may be prepared by routine methods, for example:

Methods 1 and 2 below.

[0120] Total cellular DNA is isolated from *Streptococcus pneumoniae* 0100993 according to standard procedures and size-fractionated by either of two methods.

#### Method 1

[0121] Total cellular DNA is mechanically sheared by passage through a needle in order to size-fractionate according to standard procedures. DNA fragments of up to 11kbp in size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added. Fragments are ligated into the vector Lambda ZapII that has been cut with

EcoRI, the library packaged by standard procedures and *E.coli* infected with the packaged library. The library is amplified by standard procedures.

## Method 2

[0122] Total cellular DNA is partially hydrolyzed with a one or a combination of restriction enzymes appropriate to generate a series of fragments for cloning into library vectors (e.g., RsaI, PstI, AluI, Bsh235I), and such fragments are size-fractionated according to standard procedures. EcoRI linkers are ligated to the DNA and the fragments then ligated into the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and *E.coli* infected with the packaged library. The library is amplified by standard procedures.

## Example 2

### The determination of expression during infection of a gene from *Streptococcus pneumoniae*

[0123] Excised lungs from a 48 hour respiratory tract infection of *Streptococcus pneumoniae* 0100993 in the mouse is efficiently disrupted and processed in the presence of chaotropic agents and RNAase inhibitor to provide a mixture of animal and bacterial RNA. The optimal conditions for disruption and processing to give stable preparations and high yields of bacterial RNA are followed by the use of hybridisation to a radiolabelled oligonucleotide specific to *Streptococcus pneumoniae* 16S RNA on Northern blots. The RNAase free, DNAase free, DNA and protein free preparations of RNA obtained are suitable for Reverse Transcription PCR (RT-PCR) using unique primer pairs designed from the sequence of each gene of *Streptococcus pneumoniae* 0100993.

#### a) Isolation of tissue infected with *Streptococcus pneumoniae* 0100993 from a mouse animal model of infection (lungs)

[0124] *Streptococcus pneumoniae* 0100993 is grown either on TSA/5%horse blood plates or in AGCH medium overnight, 37°C, 5%CO<sub>2</sub>. Bacteria are then collected and resuspended in phosphate-buffered saline to an A<sub>600</sub> of approximately 0.4. Mice are anaesthetized with isoflurane and 50ml of bacterial suspension (approximately 2 x 10<sup>5</sup> bacteria) is administered intranasally using a pipetman. Mice are allowed to recover and have food and water ad libitum. After 48 hours, the mice are euthanized by carbon dioxide overdose, and lungs are aseptically removed and snap-frozen in liquid nitrogen.

#### b) Isolation of *Streptococcus pneumoniae* 0100993 RNA from infected tissue samples

[0125] Infected tissue samples, in 2-ml cryo-storage tubes, are removed from -80°C storage into a dry ice ethanol bath. In a microbiological safety cabinet the samples are disrupted up to eight at a time while the remaining samples are kept frozen in the dry ice ethanol bath. To disrupt the bacteria within the tissue sample, 50-100 mg of the tissue is transferred to a FastRNA tube containing a silica/ceramic matrix (BIO101). Immediately, 1 ml of extraction reagents (FastRNA reagents, BIO101) are added to give a sample to reagent volume ratio of approximately 1 to 20. The tubes are shaken in a reciprocating shaker (FastPrep FP120, BIO101) at 6000 rpm for 20-120 sec. The crude RNA preparation is extracted with chloroform/isoamyl alcohol, and precipitated with DEPC-treated/Isopropanol Precipitation Solution (BIO101). RNA preparations are stored in this isopropanol solution at -80°C if necessary. The RNA is pelleted (12,000g for 10 min.), washed with 75% ethanol (v/v in DEPC-treated water), air-dried for 5-10 min, and resuspended in 0.1 ml of DEPC-treated water, followed by 5-10 minutes at 55°C. Finally, after at least 1 minute on ice, 200 units of Rnasin (Promega) is added.

[0126] RNA preparations are stored at -80°C for up to one month. For longer term storage the RNA precipitate can be stored at the wash stage of the protocol in 75% ethanol for at least one year at -20°C.

[0127] Quality of the RNA isolated is assessed by running samples on 1% agarose gels. 1 x TBE gels stained with ethidium bromide are used to visualise total RNA yields. To demonstrate the isolation of bacterial RNA from the infected tissue 1 x MOPS, 2.2M formaldehyde gels are run and vacuum blotted to Hybond-N (Amersham). The blot is then hybridised with a <sup>32</sup>P-labelled oligonucleotide probe, of sequence 5' AACTGAGACTGGCTTTAAGAGATTA 3' (SEQ ID NO:7), specific to 16S rRNA of *Streptococcus pneumoniae*. The size of the hybridising band is compared to that of control RNA isolated from *in vitro* grown *Streptococcus pneumoniae* 0100993 in the Northern blot. Correct sized bacterial 16S rRNA bands can be detected in total RNA samples which show degradation of the mammalian RNA when visualised on TBE gels.

c) The removal of DNA from *Streptococcus pneumoniae*-derived RNA

[0128] DNA is removed from 50 microgram samples of RNA by a 30 minute treatment at 37°C with 20 units of RNAase-free DNAaseI (GenHunter) in the buffer supplied in a final volume of 57 microliters.

[0129] The DNAase is inactivated and removed by treatment with TRIzol LS Reagent (Gibco BRL, Life Technologies) according to the manufacturers protocol. DNAase treated RNA is resuspended in 100 microlitres of DEPC treated water with the addition of Rnasin as described before.

## d) The preparation of cDNA from RNA samples derived from infected tissue

[0130] 3 microgram samples of DNAase treated RNA are reverse transcribed using a SuperScript Preamplification System for First Strand cDNA Synthesis kit (Gibco BRL, Life Technologies) according to the manufacturers instructions. 150 nanogram of random hexamers is used to prime each reaction. Controls without the addition of SuperScriptII reverse transcriptase are also run. Both +/-RT samples are treated with RNaseH before proceeding to the PCR reaction

## e) The use of PCR to determine the presence of a bacterial cDNA species

[0131] PCR reactions are set up on ice in 0.2ml tubes by adding the following components: 43 microlitres PCR Master Mix (Advanced Biotechnologies Ltd.); 1 microlitre PCR primers (optimally 18-25 basepairs in length and designed to possess similar annealing temperatures), each primer at 10mM initial concentration; and 5 microlitres cDNA.

[0132] PCR reactions are run on a Perkin Elmer GeneAmp PCR System 9600 as follows: 2 minutes at 94°C, then 50 cycles of 30 seconds each at 94°C, 50°C and 72°C followed by 7 minutes at 72°C and then a hold temperature of 20°C. (the number of cycles is optimally 30-50 to determine the appearance or lack of a PCR product and optimally 8-30 cycles if an estimation of the starting quantity of cDNA from the RT reaction is to be made); 10 microlitre aliquots are then run out on 1% 1 x TBE gels stained with ethidium bromide, with PCR product, if present, sizes estimated by comparison to a 100 bp DNA Ladder (Gibco BRL, Life Technologies). Alternatively if the PCR products are conveniently labelled by the use of a labelled PCR primer (e.g. labelled at the 5'end with a dye) a suitable aliquot of the PCR product is run out on a polyacrylamide sequencing gel and its presence and quantity detected using a suitable gel scanning system (e.g. ABI Prism™ 377 Sequencer using GeneScan™ software as supplied by Perkin Elmer).

[0133] RT/PCR controls may include +/- reverse transcriptase reactions, 16S rRNA primers or DNA specific primer pairs designed to produce PCR products from non-transcribed *Streptococcus pneumoniae* 0100993 genomic sequences.

[0134] To test the efficiency of the primer pairs they are used in DNA PCR with *Streptococcus pneumoniae* 0100993 total DNA. PCR reactions are set up and run as described above using approx. 1 microgram of DNA in place of the cDNA.

[0135] Primer pairs which fail to give the predicted sized product in either DNA PCR or RT/PCR are PCR failures and as such are uninformative. Of those which give the correct size product with DNA PCR two classes are distinguished in RT/PCR: 1. Genes which are not transcribed *in vivo* reproducibly fail to give a product in RT/PCR; and 2. Genes which are transcribed *in vivo* reproducibly give the correct size product in RT/PCR and show a stronger signal in the +RT samples than the signal (if at all present) in -RT controls

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

(A) NAME: SmithKline Beecham Corporation

(B) STREET: One Franklin Plaza

(C) CITY: Philadelphia

(D) STATE OR PROVINCE: PA

(E) COUNTRY: USA

(F) POSTAL CODE: 19103

(ii) TITLE OF INVENTION: Novel Ornithine Carbamoyl  
transferase

(iii) NUMBER OF SEQUENCES: 7

## (iv) COMPUTER-READABLE FORM:

(A) MEDIUM TYPE: Diskette

(B) COMPUTER: IBM Compatible

(C) OPERATING SYSTEM: Windows

(D) SOFTWARE: FastSEQ for Windows Version 2.0b

## (v) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2800 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAAATCGATT GATTTTCAAG AAAGATCCTT TTTCTCGGAG AAGAAGGTCA ATAGCCTGTC 60

	AAGTATGCCA GACGTCGCTA TAGAGAAATA CGTCAAAAAT GGTGAAAGA GGGAGAGTAA	120
	GAAGATGAGA ATATTTGTTT TAGAAGATGA TTTTCCCAA CAGACTAGAA TTGAAACGAC	180
5	GATTGAGAAA CTTTGGAAAG CACATCATAT CATTCTAGC TCTTTGAGG TATTGGCAA	240
	GCCGGACCAA CTGCTGGCAG AGGTACATGA GAAGGGGGCC CATCAGCTAT TCTTTTGGGA	300
	TATTGAGATT CGAAATGAAG AGATGAAGGG ACTGGAAGTA GCTAGAAAGA TTCGGGAACA	360
	AGACCCTTAT GCCCTAATCG TCTTTGTGAC GACTCACTCG GAGTTTATGC CTCTGTCCTT	420
10	TCGCTACCAA GTGTCAGCTT TGGACTACAT TGATAAGGCC CTTTCGGCAG AGGAGTTTGA	480
	ATCTCGTATC GAGACAGCCC TCCTCTATGC CAATAGTCAA GATAGTAAAA GTCTGGCGGA	540
	AGATTGCTTT TACTTTAAAT CAAAATTTGC CCAATTCCAA TATCCTTTCA AAGAGGTTTA	600
	CTATCTCGAA ACATCCCCAA GACCCCATCG TGTTATTCTC TATACCAAGA CGGACAGGCT	660
15	AGAATTTACG GCGAGTTTAG AGGAGGTTTT TAAGCAGGAA CCCAGTCTCT TGCAGTGCCA	720
	TCGCTCTTTT CTCATCAATC CTGCAAATGT GGTGCATTG GATAAGAAAG AAAAATCCT	780
	TTTCTTTCCC AATGGTGGAA GCTGTCTGAT CGCGCGTTAT AAGGTCAGGG AASTGTCTGA	840
	GGCTATTAAT AACTTACACT GAGCTAGGAG AGTTTATGAA CATTGCTTGG ATATTGTTGT	900
20	ATGCACTTGT TATTAATGGA CTAATAATTG TCATTTTCTT TAAAGTAAAT GGAATTGGTC	960
	TCATTTTCGA TAGAATTTT AAGGCCTTTC TTCTGAAATT TCTTCTAGGG ATCATTTTTA	1020
	CGACTTTTCA ATTTTGGCT GTAAGTAAAT ATTTGTCCTA TTTTATAGAA CCTTTGTTTCG	1080
	GTATAGGTCT ATCTTTCTTA TTGTTAAGAG GGCTTCCTAA AAAAATCCTT ATTTTTATG	1140
25	GTCTCTTCCC AATGATATTA GTAGAGCTCT TTTACAGAGG TGTTTCCTAT TTTGTGCTTC	1200
	CATTTTGGG GCAAGGAATT GTAGATGGG ATGGCAATCC TATCTTTTTA TTGATTATGA	1260
	TATTCGTTTG CTTCATAGTT TTAGTCTTTT TGAAATGGT AGACTATGAT TTCACTAGAT	1320
	TGAGAAGGGA GTTCTAGAT ACAGGTTTTT AAAAGTCTCT TACTAAGATT AACTGGGCAA	1380
30	TGGGGGCTTA TTATCTAGTG ATGCAAAGTC TATCTTACCT TGAATATGAA CAAGGTATTC	1440
	AATCAACGAC TGTTCCGCAT CTCATCCTAG TGTTTACCT ACTCTTTTTT ATGGGGGGTA	1500
	TCAAGAAATT GGATACCTAT TTGAAGGAAA AACTTCAGGA GGAAGTGAAC CAAGAGCAGA	1560
	CCTTGCCTA CAGAGATATG GAACGTATA GTCGGCATAT AGAGGAACTT TACAAGGAAA	1620
35	TTCGGAGTTT TCGCCATGAC TACACTAACC TCTTAACCAG CTTACGTTTG GGCATTGAAG	1680
	AGGAGGATAT GGAGCAGATA AAAGAGATCT ACGACTCGGT CTTAAGGGAT TCCAGTCAGA	1740
	AATTGCAGGA CAATAAATAT GACCTGGGCA GATTGGTGAA TATTCGTGAC CGTGCCCTCA	1800
	AGAGTCTCCT AGCTGGAAAA TTTATAAAAG CTAGAGAAAA GAACATTGTC TTTAATGTTG	1860
40	AAGTTCCTGA GGAGATTCAG GTTGAGGGGA TGAGCCTACT TGATTTCTA ACCATTGTGT	1920
	CTATCCTTTG TGACAATGCT ATTGAAGTTA GTGCAGAGGC CAGTCAACCT CATGTTTCAA	1980
	TCGCCTTTTT AAAAATGGA GCACAGGAGA CTTTTATCAT TGAAGTCC ATCAAAGAAG	2040
	AGGGCATCGA TATTTCTGAA ATCTTCTCCT TTGGAGCAAG TTCTAAAGG GAGGAGAGAG	2100
45	GAGTTGGTCT CTATACCGTT ATGAAAATTG TGGAAAGTCA TCCCAATACC AATCTAAATA	2160
	CTACCTGCCA AAATCAAGTC TTTGTCAGG TACTTACTGT GATACATGCA GAATGATAAA	2220
	AAACAAGACC GAGAGTTCTT GTTCTCGGT CTTGTTTTTA TAGCTGAATA GGTAGTTCAA	2280
	GTGCTTTTGT GATTTTAAAT TTAATAAAA TTGTTTCATG TAAGAGTTCT TCCCACCATT	2340
50	CTCCACCTGT AATTTGGTTG AGTTCGGTAG TTGTTAGTTC TTGAAATGAA GTTAGGTTTT	2400
	GTTTCTTATC CATGTTATGA TTCTCCTTTT TGATAAGATA ATAAATAGTT ATAGAGTGTT	2460

ATCTGAAAAT TAATCAGAAT GGGTTAAAAT TTTATCTTTG AAATAATCAA AATATGTTTT 2520  
 CTTTGCAGTT AACTAGTGA CGCGACCTTG TAAGCCATAT TGGATGAGTT TACTATCCTC 2580  
 5 ATTAGATAGT TTTGCAAGAG CGGTAAATTT AAAGAGATTG CCTTGCTCTG TTCTGGTAGG 2640  
 AGTTTGATCA ATTGTCTGAA GTTGGCCGAT GATGGTAATG CCGTGATTTC CAATCTTCTC 2700  
 CAGTTTTAAT CTTACAGTTT GTCCTTTATC TAGTAGAGGT AGATAGTCAG AAGCTACGTA 2760  
 10 GTAAGTGATT AGTACTTCTC TTGTATCTGT GATGATAGGG 2800

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 245 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

25 Met Arg Ile Phe Val Leu Glu Asp Asp Phe Ser Gln Gln Thr Arg Ile  
 1 5 10 15  
 Glu Thr Thr Ile Glu Lys Leu Leu Lys Ala His His Ile Ile Pro Ser  
 20 25 30  
 30 Ser Phe Glu Val Phe Gly Lys Pro Asp Gln Leu Leu Ala Glu Val His  
 35 40 45  
 Glu Lys Gly Ala His Gln Leu Phe Phe Leu Asp Ile Glu Ile Arg Asn  
 50 55 60  
 35 Glu Glu Met Lys Gly Leu Glu Val Ala Arg Lys Ile Arg Glu Gln Asp  
 65 70 75 80  
 Pro Tyr Ala Leu Ile Val Phe Val Thr Thr His Ser Glu Phe Met Pro  
 40 85 90 95  
 Leu Ser Phe Arg Tyr Gln Val Ser Ala Leu Asp Tyr Ile Asp Lys Ala  
 100 105 110  
 Leu Ser Ala Glu Glu Phe Glu Ser Arg Ile Glu Thr Ala Leu Leu Tyr  
 45 115 120 125  
 Ala Asn Ser Gln Asp Ser Lys Ser Leu Ala Glu Asp Cys Phe Tyr Phe  
 130 135 140  
 Lys Ser Lys Phe Ala Gln Phe Gln Tyr Pro Phe Lys Glu Val Tyr Tyr  
 50 145 150 155 160  
 Leu Glu Thr Ser Pro Arg Pro His Arg Val Ile Leu Tyr Thr Lys Thr  
 165 170 175



Asp Arg Leu Glu Phe Thr Ala Ser Leu Glu Glu Val Phe Lys Gln Glu  
 180 185 190  
 5 Pro Ser Leu Leu Gln Cys His Arg Ser Phe Leu Ile Asn Pro Ala Asn  
 195 200 205  
 Val Val His Leu Asp Lys Lys Glu Lys Leu Leu Phe Phe Pro Asn Gly  
 210 215 220  
 10 Gly Ser Cys Leu Ile Ala Arg Tyr Lys Val Arg Glu Val Ser Glu Ala  
 225 230 235 240  
 Ile Asn Asn Leu His  
 245

15

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

20

- (A) LENGTH: 2802 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

25

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

30 AAAATCGATT GATTTTCAAG AAAGATCCTT TTTCTCGGAG AAGAAGGTCA ATAGCCTGTC 60  
 AAGTATGCCA GACGTCGCTA TAGAGAAATA CGTCAAAAAT GGTGAAAGA GGGAGAGTAA 120  
 GAAGATGAGA ATATTTGTTT TAGAAGATGA TTTTCCCAA CAGACTAGAA TTGAAACGAC 180  
 GATTGAGAAA CTTTGAAG CACATCATAT CATTCTAGC TCTTTGAGG TATTTGGCAA 240  
 35 GCCGGACCAA CTGCTGGCAG AGGTACATGA GAAGGGGGCC CATCAGCTAT TCTTTTGGGA 300  
 TATTGAGATT CGAAATGAAG AGATGAAGGG ACTGGAAGTA GCTAGAAAGA TTCGGGAACA 360  
 AGACCCTTAT GCCCTAATCG TCTTTGTGAC GACTCACTCG GAGTTTATGC CTCTGCCTT 420  
 TCGCTACCAA GTGTCAGCTT TGGACTACAT TGATAAGGCC CTTTCGGCAG AGGAGTTTGA 480  
 40 ATCTCGTATC GAGACAGCCC TCCTCTATGC CAATAGTCAA GATAGTAAA GTCTGGCGGA 540  
 AGATTGCTTT TACTTTAAAT CAAAATTGCG CCAATTCCAA TATCCTTTCA AAGAGGTTTA 600  
 CTATCTCGAA ACATCCCCAA GACCCCATCG TGTTATTCTC TATACCAAGA CGGACAGGCT 660  
 AGAATTTACG GCGAGTTTAG AGGAGGTTTT TAAGCAGGAA CCCAGTCTCT TGCAGTGCCA 720  
 45 TCGCTCTTT CTCATCAATC CTGCAAATGT GGTGCATTTG GATAAGAAAG AAAA ACTCCT 780  
 TTTCTTTCCC AATGGTGGAA GCTGTCTGAT CGCGCGTTAT AAGGTCAGGG AAGTGTCTGA 840  
 GGCTATTAAT AACTTACACT GAGCTAGGAG AGTTTATGAA CATTGCTTGG ATATTGTTGT 900  
 ATGCACTTGT TATTAATGGA CTAAAAATTG TCATTTTCTT TAAAGTAAAT GGAATTGGTC 960  
 50 TCACTTTCGA TAGAATTTTT AAGGCCTTTC TTCTGAAATT TCTTCTAGGG ATCATTTTTA 1020  
 CGACTTTTCA ATTTTGGCT GTAAGTAAAT ATTTGTCCTA TTTTATAGAA CCTTTGTTTCG 1080

55

GTATAGGTCT ATCTTTCTTA TTGTTAAGAG GGCTTCCTAA AAAAATCCTT ATTTTTTATG 1140  
 GTCTCTTCCC AATGATATTA GTAGAGCTCT TTTACAGAGG TGTTTCCTAT TTTGTGCTTC 1200  
 5 CATT TTTGGG GCAAGGAATT GTAGATGGGG ATGGCAATCC TATCTTTTTA TTGATTATGA 1260  
 TATTTCGTTTG CTTCATAGTT TTAGTCTTTT TGAAATGGTT AGACTATGAT TTCACTAGAT 1320  
 TGAGAAGGGA GTTCTAGAT ACAGGTTTTT AAAAGTCTCT TACTAAGATT AACTGGGCAA 1380  
 TGGGGGCTTA TTATCTAGTG ATGCAAAGTC TATCTTACCT TGAATATGAA CAAGGTATTC 1440  
 10 AATCAACGAC TGTTCCGCAT CTCATCCTAG TGTTTTACCT ACTCTTTTTT ATGGGGGGTA 1500  
 TCAAGAAATT GGATACCTAT TTGAAGGAAA AACTTCAGGA GGAAGTGAAC CAAGAGCAGA 1560  
 CCTTGCCTA CAGAGATATG GAACGCTATA GTCGGCATAT AGAGGAACTT TACAAGGAAA 1620  
 TTCGGAGTTT TCGCCATGAC TACACTAACC TCTTAACCAG CTTACGTTTG GGCATTGAAG 1680  
 15 AGGAGGATAT GGAGCAGATA AAAGAGATCT ACGACTCGGT CTTAAGGGAT TCCAGTCAGA 1740  
 AATTGCAGGA CAATAAATAT GACCTGGGCA GATTGGTGAA TATTCGTGAC CGTGCCCTCA 1800  
 AGAGTCTCCT AGCTGGAAAA TTTATAAAAG CTAGAGAAAA GAACATTGTC TTTAATGTTG 1860  
 AAGTTCCTGA GGAGATTCAG GTTGAGGGGA TGAGCCTACT TGATTTTCTA ACCATTGTGT 1920  
 20 CTATCCTTTG TGACAATGCT ATTGAAGTTA GTGCAGAGGC CAGTCAACCT CATGTTTCAA 1980  
 TCGCCTTTT AAAAATGGA GCACAGGAGA CTTTTATCAT TGAAACTCC ATCAAAGAAG 2040  
 AGGGCATCGA TATTTCTGAA ATCTTCTCCT TTGGAGCAAG TTCTAAAGGG GAGGAGAGAG 2100  
 GAGTTGGTCT CTATACCGTT ATGAAAATTG TGGAAAGTCA TCCAATACC AATCTAAATA 2160  
 25 CTACCTGCCA AAATCAAGTC TTTCTGTCAGG TACTTACTGT GATACATGCA GAATGATAAA 2220  
 AAACAAGACC GAGAGTCTT GTTTCTCGGT CTTGTTTTTA TAGCTGAATA GG TAGTTCAA 2280  
 GTGCTTTTGT GATTTTAAAT TACTTAAAA TTGTTTCATG TAAGAGTTCT TCCCACCATT 2340  
 CTCCACCTGT AATTTGGTTG AGTTCGGTAG TTGTTAGTTC TTGAAATGAA GTTAGGTTTT 2400  
 30 GTTCTTATC CATGTTATGA TTCTCCTTTT TGATAAGATA ATAAATAGTT ATAGAGTGTT 2460  
 ATCTGAAAAT TAATCAGAAT GGGTTAAAT TTTATCTTTG AAATAATCAA AATATGTTTT 2520  
 CTTTGCAGTT ACACTAGTGA CGCGACCTTG TAAGCCATAT TGGATGAGTT TACTATCCTC 2580  
 ATTAGATAGT TTTGCAAGAG CGGTAAATTT AAAGAGATTG CCTTGCTCTG TTCTGGTAGG 2640  
 35 AGTTTGATCA ATTGCTGAA GTTGGCCGAT GATGGTAATG CCGTGATTTC CAATCTTCTC 2700  
 CAGTTTTAAT CTTACAGTTT GTCCTTTATC TAGTAGAGGT AGATAGTCAG AAGCTACGTA 2760  
 GTAAGTGATT AGTACTTCTC TTGTATCTGT GATGATAGGG -' 2802

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 447 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Asn Ile Ala Trp Ile Leu Leu Tyr Ala Leu Val Ile Asn Gly Leu  
 1 5 10 15  
 5 Lys Ile Val Ile Phe Phe Lys Val Asn Gly Ile Gly Leu Thr Phe Asp  
 20 25 30  
 Arg Ile Phe Lys Ala Phe Leu Leu Lys Phe Leu Leu Gly Ile Ile Phe  
 35 40 45  
 10 Thr Thr Phe Gln Phe Leu Ala Val Ser Lys Tyr Leu Ser Tyr Phe Ile  
 50 55 60  
 Glu Pro Leu Phe Gly Ile Gly Leu Ser Phe Leu Leu Leu Arg Gly Leu  
 65 70 75 80  
 15 Pro Lys Lys Ile Leu Ile Phe Tyr Gly Leu Phe Pro Met Ile Leu Val  
 85 90 95  
 Glu Leu Phe Tyr Arg Gly Val Ser Tyr Phe Val Leu Pro Phe Leu Gly  
 100 105 110  
 20 Gln Gly Ile Val Asp Gly Asp Gly Asn Pro Ile Phe Leu Leu Ile Met  
 115 120 125  
 Ile Phe Val Cys Phe Ile Val Leu Val Phe Leu Lys Trp Leu Asp Tyr  
 130 135 140  
 25 Asp Phe Thr Arg Leu Arg Arg Glu Phe Leu Asp Thr Gly Phe Gln Lys  
 145 150 155 160  
 Ser Leu Thr Lys Ile Asn Trp Ala Met Gly Ala Tyr Tyr Leu Val Met  
 165 170 175  
 30 Gln Ser Leu Ser Tyr Leu Glu Tyr Glu Gln Gly Ile Gln Ser Thr Thr  
 180 185 190  
 Val Arg His Leu Ile Leu Val Phe Tyr Leu Leu Phe Phe Met Gly Gly  
 195 200 205  
 35 Ile Lys Lys Leu Asp Thr Tyr Leu Lys Glu Lys Leu Gln Glu Glu Leu  
 210 215 220  
 Asn Gln Glu Gln Thr Leu Arg Tyr Arg Asp Met Glu Arg Tyr Ser Arg  
 225 230 235 240  
 40 His Ile Glu Glu Leu Tyr Lys Glu Ile Arg Ser Phe Arg His Asp Tyr  
 245 250 255  
 Thr Asn Leu Leu Thr Ser Leu Arg Leu Gly Ile Glu Glu Glu Asp Met  
 260 265 270  
 45 Glu Gln Ile Lys Glu Ile Tyr Asp Ser Val Leu Arg Asp Ser Ser Gln  
 275 280 285  
 50 Lys Leu Gln Asp Asn Lys Tyr Asp Leu Gly Arg Leu Val Asn Ile Arg  
 290 295 300  
 Asp Arg Ala Leu Lys Ser Leu Leu Ala Gly Lys Phe Ile Lys Ala Arg

55

305                      310                      315                      320  
 Glu Lys Asn Ile Val Phe Asn Val Glu Val Pro Glu Glu Ile Gln Val  
 5                      325                      330                      335  
 Glu Gly Met Ser Leu Leu Asp Phe Leu Thr Ile Val Ser Ile Leu Cys  
 340                      345                      350  
 Asp Asn Ala Ile Glu Val Ser Ala Glu Ala Ser Gln Pro His Val Ser  
 10                      355                      360                      365  
 Ile Ala Phe Leu Lys Asn Gly Ala Gln Glu Thr Phe Ile Ile Glu Asn  
 370                      375                      380  
 Ser Ile Lys Glu Glu Gly Ile Asp Ile Ser Glu Ile Phe Ser Phe Gly  
 15                      385                      390                      395                      400  
 Ala Ser Ser Lys Gly Glu Glu Arg Gly Val Gly Leu Tyr Thr Val Met  
 405                      410                      415  
 Lys Ile Val Glu Ser His Pro Asn Thr Asn Leu Asn Thr Thr Cys Gln  
 20                      420                      425                      430  
 Asn Gln Val Phe Arg Gln Val Leu Thr Val Ile His Ala Glu  
 435                      440                      445

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AAAAACGCAA TATTCAACAC CACT

24

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

5 TCCTTCTGCC AATTCAACGA T 21

(2) INFORMATION FOR SEQ ID NO:7:

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

15 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

20 AACTGAGACT GGCTTTAAGA GATTA 25

25

### Claims

- 30 1. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:
- (a) a polynucleotide having at least a 70% identity to a polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2;
  - (b) a polynucleotide having at least a 70% identity to a polynucleotide encoding the same mature polypeptide expressed by the ornithine carbamoyltransferase gene contained in the *Streptococcus pneumoniae* of the deposited strain;
  - (c) a polynucleotide encoding a polypeptide comprising an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ID NO:2;
  - (d) a polynucleotide which is complementary to the polynucleotide of (a), (b) or (c); and
  - 40 (e) a polynucleotide comprising at least 15 sequential bases of the polynucleotide of (a), (b), (c) or (d).
2. The polynucleotide of Claim 1 wherein the polynucleotide is DNA.
3. The polynucleotide of Claim 1 wherein the polynucleotide is RNA.
- 45 4. The polynucleotide of Claim 2 comprising the nucleic acid sequence set forth in SEQ ID NO:1.
5. The polynucleotide of Claim 2 comprising nucleotide 1 to 1014 set forth in SEQ ID NO:1.
- 50 6. The polynucleotide of Claim 2 which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
7. A vector comprising the polynucleotide of Claim 1.
8. A host cell comprising the vector of Claim 7.
- 55 9. A process for producing a polypeptide comprising: expressing from the host cell of Claim 8 a polypeptide encoded by said DNA.

10. A process for producing a ornithine carbamoyltransferase polypeptide or fragment comprising culturing a host of claim 8 under conditions sufficient for the production of said polypeptide or fragment.

11. A polypeptide comprising an amino acid sequence which is at least 70% identical to the amino acid sequence of SEQ ID NO:2.

12. A polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2.

13. An antibody against the polypeptide of claim 11.

14. An antagonist which inhibits the activity or expression of the polypeptide of claim 11.

15. A method for the treatment of an individual in need of ornithine carbamoyltransferase polypeptide comprising: administering to the individual a therapeutically effective amount of the polypeptide of claim 11.

16. A method for the treatment of an individual having need to inhibit ornithine carbamoyltransferase polypeptide comprising: administering to the individual a therapeutically effective amount of the antagonist of Claim 14.

17. A process for diagnosing a disease related to expression or activity of the polypeptide of claim 11 in an individual comprising:

- (a) determining a nucleic acid sequence encoding said polypeptide, and/or
- (b) analyzing for the presence or amount of said polypeptide in a sample derived from the individual.

18. A method for identifying compounds which interact with and inhibit or activate an activity of the polypeptide of claim 11 comprising:

contacting a composition comprising the polypeptide with the compound to be screened under conditions to permit interaction between the compound and the polypeptide to assess the interaction of a compound, such interaction being associated with a second component capable of providing a detectable signal in response to the interaction of the polypeptide with the compound;  
and determining whether the compound interacts with and activates or inhibits an activity of the polypeptide by detecting the presence or absence of a signal generated from the interaction of the compound with the polypeptide.

19. A method for inducing an immunological response in a mammal which comprises inoculating the mammal with ornithine carbamoyltransferase polypeptide of claim 11, or a fragment or variant thereof, adequate to produce antibody and/or T cell immune response to protect said animal from disease.

20. A method of inducing immunological response in a mammal which comprises delivering a nucleic acid vector to direct expression of ornithine carbamoyltransferase polypeptide of claim 11, or fragment or a variant thereof, for expressing said ornithine carbamoyltransferase polypeptide, or a fragment or a variant thereof *in vivo* in order to induce an immunological response to produce antibody and/or T cell immune response to protect said animal from disease.

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 913 476 A3**

(12)

**EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
**01.03.2000 Bulletin 2000/09**

(51) Int. Cl.<sup>7</sup>: **C12N 15/54**, C12N 9/10,  
C12N 5/10, C07K 16/40,  
C12Q 1/68, A61K 48/00

(43) Date of publication A2:  
**06.05.1999 Bulletin 1999/18**

(21) Application number: **98203571.9**

(22) Date of filing: **22.10.1998**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **30.10.1997 US 961536**

(71) Applicant:  
**SMITHKLINE BEECHAM CORPORATION**  
**Philadelphia Pennsylvania 19103 (US)**

(72) Inventors:

- **Zalacain, Magdalena,**  
**SmithKline Beecham Pharm.**  
**Collegeville, PA 19426-0989 (US)**
- **Brown, James Raymond,**  
**SmithKline Beecham Pharm.**  
**Collegeville, PA 19426-0989 (US)**

(74) Representative:  
**Mallalieu, Catherine Louise et al**  
**D. Young & Co.,**  
**21 New Fetter Lane**  
**London EC4A 1DA (GB)**

(54) **Ornithine carbamoyl transferase sequence and uses thereof**

(57) The invention provides ornithine carbamoyl-transferase polypeptides and DNA (RNA) encoding ornithine carbamoyltransferase polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ornithine carbamoyltransferase polypeptides to screen for antibacterial compounds.

EP 0 913 476 A3



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 98 20 3571 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
A	MARSHALL M ET AL: "Ornithine transcarbamylase from Streptococcus faecalis and bovine liver. II. Multiple binding sites for carbamyl-P and L-norvaline, correlation with steady state kinetics." JOURNAL OF BIOLOGICAL CHEMISTRY, (1972 MAR 25) 247 (6) 1654-68., XP000856066 * the whole document *	1-13, 15-20	C12N15/54 C12N9/10 C12N5/10 C07K16/40 C12Q1/68 A61K48/00
A	MARSHALL M ET AL: "Ornithine transcarbamylase from Streptococcus faecalis and bovine liver. III. Effects of chemical modifications of specific residues on ligand binding and enzymatic activity." JOURNAL OF BIOLOGICAL CHEMISTRY, (1972 MAR 25) 247 (6) 1669-82., XP000856064 * the whole document *	1-13, 15-20	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C12N C07K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
BERLIN		23 November 1999	ALCONADA RODRIG..., A
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>&amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 01/83 (P04C07)





European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 98 20 3571

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	TRICOT C ET AL: "Evolutionary relationships among bacterial carbamoyltransferases." JOURNAL OF GENERAL MICROBIOLOGY, (1989 SEP) 135 ( PT 9) 2453-64., XP000856002 * the whole document *	1-13, 15-20	
A	WO 96 05859 A (AMERICAN CYANAMID CO) 29 February 1996 (1996-02-29) * examples 9-13 * * tables 1-7 *	13,16,19	
P,X	WO 98 18931 A (DOUGHERTY BRIAN A ;HUMAN GENOME SCIENCES INC (US); ROSEN CRAIG A ( ) 7 May 1998 (1998-05-07) *SEQ ID NO 189* *SEQ ID NO 190* * page 106 * * page 116 * * page 15, line 3-10 * * page 21, line 19-28 * * page 22, line 10-15,22-32 * * page 32, line 15-20 * * page 34, line 18-20 * * page 37, line 19-36 *	1-9, 11-13, 15-20	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
P,X	WO 97 43303 A (NICHOLAS RICHARD OAKLEY ;KNOWLES DAVID JUSTIN CHARLES (GB); HODGSO) 20 November 1997 (1997-11-20) *SEQ ID NO 326* *SEQ ID NO 327* * page 40 * * page 8, line 28-34 * * page 13, line 22-24 * * page 25, line 24-28 * * page 23, line 9-12 *	1-9, 11-13, 15-20	
	---		
	-/--		



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 98 20 3571

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
T	<p>DATABASE GENEMBL [Online] 2 September 1999 (1999-09-02) LANGE R.: "Streptococcus pneumoniae rr13 and hk13 genes; two component system" XP002123504 *Accession AJ006401* &amp; LANGE, R. ET AL.: "Domain organization and molecular characterization of 13 two-component systems by genome sequencing of Streptococcus pneumoniae" GENE, vol. 237, 2 September 1999 (1999-09-02), pages 223-234, * the whole document *</p> <p>---</p>	1-6	
E, L	<p>EP 0 885 901 A (SMITHKLINE BEECHAM PLC ;SMITHKLINE BEECHAM CORP (US)) 23 December 1998 (1998-12-23) *SEQ ID NO 1* *SEQ ID NO 5* * claims 1-20 * 100% sequence identity with SEQ ID NOs 1 and 2 over their entire length</p> <p>---</p>	1-9, 11-13, 15-20	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
E, L	<p>EP 0 892 059 A (SMITHKLINE BEECHAM PLC ;SMITHKLINE BEECHAM CORP (US)) 20 January 1999 (1999-01-20) *SEQ ID NO 1* *SEQ ID NO 3* * claims 1-20 * 100% sequence identity with SEQ ID NOs 1 and 2 over their entire length</p> <p>---</p> <p>-/--</p>	1-9, 11-13, 15-20	



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 98 20 3571

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
E, L	EP 0 885 963 A (SMITHKLINE BEECHAM PLC ; SMITHKLINE BEECHAM CORP (US)) 23 December 1998 (1998-12-23) *SEQ ID NO 1* *SEQ ID NO 3* * claims 1-20 * 100% sequence identity with SEQ ID NOs 1 and 2 over their entire length -----	1-9, 11-13, 15-20	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)

EPO FORM 1500 03.82 (P04C10)



European Patent  
Office

INCOMPLETE SEARCH  
SHEET C

Application Number  
EP 98 20 3571

Although claims 15, 16, 19 and 20 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

-----

Claim(s) not searched:  
14

Reason for the limitation of the search:

Claim 14 refers to an antagonist/inhibitor of the polypeptide without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 84 EPC).

No search could be carried out for such purely speculative claims whose wording is, in fact, a mere recitation of the result to be achieved.

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 20 3571

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

23-11-1999

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9605859	A	29-02-1996	US	5565204 A	15-10-1996
			AU	704450 B	22-04-1999
			AU	3363695 A	14-03-1996
			CA	2198251 A	29-02-1996
			EP	0778781 A	18-06-1997
			JP	10504717 T	12-05-1998
-----					
WO 9818931	A	07-05-1998	AU	5194598 A	22-05-1998
			AU	6909098 A	22-05-1998
			EP	0942983 A	22-09-1999
			EP	0941335 A	15-09-1999
			WO	9818930 A	07-05-1998
-----					
WO 9743303	A	20-11-1997	EP	0934336 A	11-08-1999
			EP	0914330 A	12-05-1999
			WO	9743304 A	20-11-1997
-----					
EP 0885901	A	23-12-1998	US	5882889 A	16-03-1999
			CA	2234424 A	13-12-1998
			JP	11098993 A	13-04-1999
-----					
EP 0892059	A	20-01-1999	CA	2235422 A	20-12-1998
			JP	11123088 A	11-05-1999
-----					
EP 0885963	A	23-12-1998	CA	2235444 A	20-12-1998
			JP	11146792 A	02-06-1999
-----					

